Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
TARA Protara Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: TARA
Price (delayed)
$2.88
Market cap
$111.12M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.67
Enterprise value
$23.88M
Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara's portfolio includes its lead program, TARA-002, an investigational cell-based
Highlights
Protara Therapeutics's quick ratio has soared by 76% YoY and by 14% from the previous quarter
The EPS has soared by 55% year-on-year and by 23% since the previous quarter
The equity has surged by 171% year-on-year but it has declined by 5% since the previous quarter
The company's net income fell by 7% YoY
Key stats
What are the main financial stats of TARA
Market
Valuations
Earnings
Shares outstanding
38.58M
Market cap
$111.12M
Enterprise value
$23.88M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.67
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$51.43M
Net income
-$45.42M
EBIT
-$45.42M
EBITDA
-$45.08M
Free cash flow
-$40.25M
Per share
Balance sheet
Liquidity
EPS
-$1.67
EPS diluted
-$1.67
Free cash flow per share
-$0.99
Book value per share
$4.31
Revenue per share
$0
TBVPS
$4.14
Total assets
$168.56M
Total liabilities
$10.08M
Debt
$4.23M
Equity
$158.48M
Working capital
$119.51M
Debt to equity
0.03
Current ratio
18.03
Quick ratio
17.72
Net debt/EBITDA
1.93
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-33.3%
Return on equity
-36.4%
Return on invested capital
-133.3%
Return on capital employed
-28.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TARA stock price
How has the Protara Therapeutics stock price performed over time
Intraday
-3.36%
1 week
-5.57%
1 month
-8.86%
1 year
32.72%
YTD
-45.45%
QTD
-32.39%
Financial performance
How have Protara Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$51.43M
Net income
-$45.42M
Gross margin
N/A
Net margin
N/A
TARA's operating income is down by 12% year-on-year and by 4.6% since the previous quarter
The company's net income fell by 7% YoY
Price vs fundamentals
How does TARA's price correlate with its fundamentals
Growth
What is Protara Therapeutics's growth rate over time
Valuation
What is Protara Therapeutics stock price valuation
P/E
N/A
P/B
0.67
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 55% year-on-year and by 23% since the previous quarter
The equity has surged by 171% year-on-year but it has declined by 5% since the previous quarter
TARA's P/B is 12% above its 5-year quarterly average of 0.6 and 12% above its last 4 quarters average of 0.6
Efficiency
How efficient is Protara Therapeutics business performance
TARA's return on invested capital is up by 42% since the previous quarter but it is down by 33% year-on-year
TARA's ROE is up by 38% year-on-year and by 19% since the previous quarter
The ROA has grown by 35% YoY and by 17% from the previous quarter
Dividends
What is TARA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TARA.
Financial health
How did Protara Therapeutics financials performed over time
The total assets has surged by 147% year-on-year but it has declined by 7% since the previous quarter
Protara Therapeutics's quick ratio has soared by 76% YoY and by 14% from the previous quarter
The debt is 97% less than the equity
The equity has surged by 171% year-on-year but it has declined by 5% since the previous quarter
Protara Therapeutics's debt to equity has plunged by 67% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.